Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384875 · ClinicalTrials.gov registry record · NA
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
A NA study, sponsored by CytoSorbents.
- Terminated
- Registry status
- NA
- Development phase
- 186
- Enrollment target
NCT03384875: Clinical Trial NA study, sponsored by CytoSorbents.
NCT03384875 is a NA study that was terminated before completion, run by CytoSorbents. The registered enrollment target is 186 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03384875, a NA study, was terminated before completion, sponsored by CytoSorbents.
- TERMINATED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
Study Summary
Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
Primary Outcome
Incidence and severity of AKI in the first 48 hours after CPB, evaluated based on creatinine levels at CPB, 24 \& 48h after CPB and urine output up to 48h.
Interventions
- DEVICE CytoSorb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2022-01-18 |
| Phase | NA |
Why NCT03384875 stopped before completion
NCT03384875 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which CytoSorb is the first listed.
NCT03384875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03384875 about?
NCT03384875 is a clinical study titled "CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery". Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
What is the current status of trial NCT03384875?
This trial is currently terminated. It is a NA study. The enrollment target is 186 participants. The study started on 2018-04-19. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT03384875?
The interventions under investigation include: CytoSorb (DEVICE).
Who is sponsoring clinical trial NCT03384875?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03384875's enrollment target sits among peer trials
186 579th of 2000 higher than 1,421 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI